Gastroenterology
Volume 136, Issue 1 , Pages 138-148 , January 2009

Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease

  • Anna S. Lok

      Affiliations

    • Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan
    • Corresponding Author InformationAddress requests for reprints to: Anna S. Lok, MD, Division of Gastroenterology, University of Michigan Hospitals, 3912 Taubman Center, SPC 5362, Ann Arbor, Michigan 48109. fax: (734) 936-7392
    • ,
  • Leonard B. Seeff

      Affiliations

    • Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • Timothy R. Morgan

      Affiliations

    • Division of Gastroenterology, University of California-Irvine, Irvine, California, and Gastroenterology Service, VA Long Beach Healthcare System, Long Beach, California
    • ,
  • Adrian M. di Bisceglie

      Affiliations

    • Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, Missouri
    • ,
  • Richard K. Sterling

      Affiliations

    • Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia
    • ,
  • Teresa M. Curto

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • ,
  • Gregory T. Everson

      Affiliations

    • Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, Colorado
    • ,
  • Karen L. Lindsay

      Affiliations

    • Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California
    • ,
  • William M. Lee

      Affiliations

    • Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Herbert L. Bonkovsky

      Affiliations

    • Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, Connecticut
    • ,
  • Jules L. Dienstag

      Affiliations

    • Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Marc G. Ghany

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • Chihiro Morishima

      Affiliations

    • Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, Washington, DC
    • ,
  • Zachary D. Goodman

      Affiliations

    • Division of Hepatic Pathology and the Veterans Administration Special Reference Laboratory for Pathology, Armed Forces Institute of Pathology, Washington, DC
    • ,
  • HALT-C Trial Group

Received 27 May 2008 ,Accepted 11 September 2008.

References 

  1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52
  2. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–398
  3. Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744–749
  4. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472
  5. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis (A case-control study). Ann Intern Med. 1992;116:97–102
  6. Bege T, Le Treut YP, Hardwigsen J, et al. Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver (A 116-case European series). J Gastrointest Surg. 2007;11:619–625
  7. Lawson A, Hagan S, Rye K, et al. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol. 2007;47:37–45
  8. Bralet MP, Regimbeau JM, Pineau P, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000;32:200–204
  9. Le Treut YP, Pons J, Hardwigsen J, et al. Hepatocellular carcinoma in a non-cirrhotic liver (Presentation of series of 77 operated patients). Chirurgie. 1999;124:485–493
  10. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers (A clinico-histopathologic study of 804 North American patients). Am J Clin Pathol. 1996;105:65–75
  11. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  12. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771–3777
  13. Parkin D. Cancer incidence in five countries. Lyon: IARC Scientific Publications; 2002;
  14. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group (Inhibition of hepatocarcinogenesis by interferon therapy). Ann Intern Med. 1999;131:174–181
  15. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C (Osaka Hepatocellular Carcinoma Prevention Study Group). Ann Intern Med. 1998;129:94–99
  16. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141–147
  17. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–1055
  18. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004;25:472–492
  19. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with peginterferon: the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial. New Engl J Med. In press.
  20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  21. Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?. Cancer. 2000;88:538–543
  22. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526
  23. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117:1164–1172
  24. Craxi A, Camma C. Prevention of hepatocellular carcinoma. Clin Liver Dis. 2005;9:329–346
  25. Arase Y, Ikeda K, Suzuki F, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol. 2007;79:1095–1102
  26. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985–994
  27. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–114
  28. Saito Y, Saito H, Tada S, et al. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepatogastroenterology. 2005;52:1491–1496
  29. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(Suppl 1):S74–S83
  30. Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127:1372–1380
  31. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127(Suppl 1):S17–S26
  32. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96:1127–1134
  33. Imazeki F, Yokosuka O, Fukai K, et al. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. 2005;25:772–778
  34. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  35. Bruix J, Sherman M, Llovet JM, et al. European Association for the Study of the Liver Clinical management of hepatocellular carcinoma (Conclusions of the Barcelona-2000 EASL Conference). J Hepatol. 2001;35:421–430
  36. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005;128:1752–1764
  37. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684
  38. Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43:1295–1302
  39. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population-based case control study. Gut. 2005;54:533–539
  40. Fujita Y, Shibata A, Ogimoto I, et al. The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer. 2006;94:737–739
  41. Franceschi S, Montella M, Polesel J, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev. 2006;15:683–689
  42. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 1):S72–S78
  43. Said A, Williams J, Holden J, et al. The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting. Clin Gastroenterol Hepatol. 2004;2:928–934
  44. Pekow JR, Bhan AK, Zheng H, et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer. 2007;109:2490–2496
  45. Kumar D, Farrell GC, Kench J, et al. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395–1400
  46. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–1354
  47. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212–2222
  48. Kubo S, Tanaka H, Shuto T, et al. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res. 2004;30:221–225
  49. Giannini EG, Risso D, Testa R, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:1378–1384
  50. Bonis PA, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol. 1999;94:1605–1612
  51. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology. 1996;23:1112–1118
  52. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37:520–527
  53. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O, et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. Clin Oncol (R Coll Radiol). 2007;19:197–203
  54. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282–292

 H.L.B.'s current address is Carolinas Medical Center, Charlotte, North Carolina.

 The authors disclose the following: Financial relationships of the authors with Hoffmann–La Roche, Inc, are as follows: A. S. Lok is a consultant; T. R. Morgan is a consultant, on the speaker's bureau, and receives research support; A. M. Di Bisceglie is a consultant, on the speaker's bureau, and receives research support; R. K. Sterling is a consultant, on the speaker's bureau, and receives research support; G. T. Everson is a consultant, on the speaker's bureau, and receives research support; K. L. Lindsay is a consultant and receives research support; W. M. Lee receives research support; H. L. Bonkovsky receives research support. Authors with no financial relationships related to this project are L. B. Seeff, T. M. Curto, J. L. Dienstag, M. G. Ghany, C. Morishima, and Z. D. Goodman. Potential investigator conflict of interest was disclosed to study participants.

 Supported by the National Institute of Diabetes and Digestive and Kidney Diseases (contract numbers are listed in Appendix 1); the National Institute of Allergy and Infectious Diseases (NIAID); the National Cancer Institute; the National Center for Minority Health and Health Disparities; General Clinical Research Center grants from the National Center for Research Resources, National Institutes of Health (grant numbers are listed in Appendix 1); and by Hoffman–La Roche, Inc, through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health.

 This is publication No. 34 from the HALT-C Trial Group.

 The HALT-C Trial was registered with clinicaltrials.gov (NCT00006164).

PII: S0016-5085(08)01679-X

doi: 10.1053/j.gastro.2008.09.014

Gastroenterology
Volume 136, Issue 1 , Pages 138-148 , January 2009

Article Tools

* Image Usage & Resolution